Narasin

Narasin is a cationic ionophore antibiotic and coccidiostat agent. Narasin inhibits NF-κB signaling and induces tumor cells apoptosis. Narasin has antimicrobial, antiviral anticancer activity. Narasin inhibits tumor metastasis and growth of ERα‑positive breast cancer cells by inactivation of the TGF-β/SMAD3 and IL‑6/STAT3 signaling pathways^[1][2][3]. In Vitro:Narasin (1-25 ng/mL, 48 h) increases the percentage of phosphatidylserine exposing erythrocytes, cytosolic Ca²⁺ activity ([Ca²⁺]_i) and the ceramide abundance at the erythrocyte surface^[1].
Narasin (0-10 μM, 72 h) inhibits DENV2 infection with an IC₅₀ value of 0.39 μM^[2].
Narasin (0-10 μM, 72 h) significantly inhibits the cell viability of MCF-7, T47D and MDA-MB-231 cells, with respective IC₅₀ values of 2.219, 3.562 and 11.76 µM^[3].
Narasin (2.5-5 µM, 24 h) inhibits cell migration and invasion by suppressing EMT in ER+ BC cells^[3].
In Vivo:Narasin (0.5 mg/kg or 1.5 mg/kg; i.p., every 2 days for 50 consecutive days) inhibits tumor growth and angiogenesis in xenograft mice model with MCF-7 cells^[3].